Form 4: Organon Director Robert Essner Boosts Holdings with Phantom Stock Acquisition

Organon & Co. Director Robert Essner has increased his beneficial ownership in the company through the acquisition of phantom stock units, as disclosed in a recent SEC Form 4 filing.

Summary

• Robert Essner, a Director of Organon & Co. (OGN), reported the acquisition of 23,904.382 phantom stock units.
• The transaction occurred on June 13, 2025, with each phantom stock unit valued at $10.04.
• Phantom stock units are an economic equivalent of one share of Organon common stock and are payable in cash upon settlement after the reporting person's termination of service as a director.
• Following this transaction, Mr. Essner's total beneficial ownership of phantom stock units increased to 62,702.652.
• The reported holdings include phantom stock units acquired through dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025, and June 12, 2025.

Sentiment

Score: 6

Explanation: Slightly positive. While a routine filing, a director increasing their stake (even in phantom stock) can be interpreted as a vote of confidence in the company's future, which is generally a positive signal for investors.

Positives

• The acquisition of additional phantom stock units by a director can signal continued confidence in the company's future performance and strategic direction.
• The increase in beneficial ownership aligns the director's interests more closely with those of the shareholders.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine disclosure of an insider transaction, common across all publicly traded companies. It reflects a director's compensation and investment activity within the pharmaceutical and healthcare industry, where Organon & Co. operates.

Stakeholder Impact

• Shareholders: The increase in director holdings may be viewed positively as it aligns management interests with shareholder interests, potentially signaling confidence in the company's long-term value.
• Employees: No direct impact mentioned.

Next Steps

• Ongoing reporting of beneficial ownership changes by Robert Essner as required by Section 16(a) of the Securities Exchange Act of 1934.

Key Dates

Keywords

Organon & Co., OGN, Robert Essner, SEC Form 4, Insider Transaction, Phantom Stock, Director Holdings, Equity Compensation, Beneficial Ownership